First FDA Approved Study of Stem Cells to Treat Hearing Loss

Children’s Memorial Hermann Hospital and Cord Blood Registry® (CBR) are
launching the first FDA-approved, Phase I safety study on the use of
cord blood stem cells to treat children with sensorineural hearing loss.

The study, which will use patients’ stem cells from their own stored
umbilical cord blood, is the first of its kind, and has the potential to
restore hearing. This follows evidence from published laboratory
studies that cord blood helps repair damaged organs in the inner ear.

The year-long study will follow 10 children, ages 6 weeks to 18 months, who have sustained post-birth hearing loss.

To view the multimedia assets associated with this release, please visit: